DALLAS, July 22, 2021 /PRNewswire/ -- Lantern
Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical
company using its proprietary RADR® artificial intelligence
("A.I.") platform to improve drug discovery and development, and
identify patients who will benefit from its portfolio of targeted
oncology therapeutics, announced today that it will host a
conference call and live webcast on Thursday, July 29, 2021 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss financial and
operating results for the second quarter ended June 30, 2021. The call will be led by
Panna Sharma, President and Chief
Executive Officer. He will be joined on the call by other members
of the management team.
Conference Call
Toll-free US and Canada: 800–791–4813 – conference ID#
20284
International: 785–424–1102 – conference ID# 20284
Replay Number: 1-800-839–5642, no passcode. Available
through 11:59 pm ET on August 29, 2021.
Webcast
Live webcast will be available at: Lantern
Pharma 2Q21 Earnings Call Webcast
The webcast will be archived on https://ir.lanternpharma.com
through 11:59 pm ET on August 29, 2021.
About Lantern Pharma
Lantern Pharma (LTRN) is a
clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. platform and
machine learning to discover biomarker signatures that identify
patients most likely to respond to its pipeline of
genomically-targeted therapeutics. Lantern is currently developing
four drug candidates and an ADC program across seven disclosed
tumor targets, including two phase 2 programs. By targeting drugs
to patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes. More
information is available at: www.lanternpharma.com and
Twitter@lanternpharma.
Contact
Panna Sharma,
CEO
IR@lanternpharma.com
(628)777-3339
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying
drug candidates and patient populations that are likely to respond
to a drug candidate; our strategic plans to advance the development
of our drug candidates and antibody drug conjugate (ADC)
development program; estimates regarding the development timing for
our drug candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the
drug development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "should," "will," "would," or the
negative of these words or other similar expressions) should be
considered forward-looking statements. There are a number of
important factors that could cause our actual results to differ
materially from those indicated by the forward-looking statements,
such as (i) the impact of the COVID-19 pandemic, (ii) the risk that
none of our product candidates has received FDA marketing approval,
and we may not be able to successfully initiate, conduct, or
conclude clinical testing for or obtain marketing approval for our
product candidates, (iii) the risk that no drug product based on
our proprietary RADR A.I. platform has received FDA marketing
approval or otherwise been incorporated into a commercial product,
and (iv) those other factors set forth in the Risk Factors section
in our Annual Report on Form 10-K for the year ended December
31, 2020, filed with the Securities and Exchange Commission
on March 10, 2021. You may access our Annual Report on Form
10-K for the year ended December 31, 2020 under the
investor SEC filings tab of our website
at www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-thursday-july-29-2021-at-430-pm-et-301339870.html
SOURCE Lantern Pharma